Biotechnology and bioengineeringJun 3, 2026

Continuous Purification of Lab-Made mRNA Using Advanced Membrane Technology

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

High-performance countercurrent membrane purification may support continuous purification of in vitro-transcribed mRNA.

Evidence

A platform experiment with two model mRNA constructs removed 99.7% of CTPs at 60 min, ran for more than 24 h without fouling, and maintained >97% mRNA yield with >94% Proteinase K removal.

Caveat

Proteinase K removal fell when mRNA was present because of protein-mRNA complexation, and the study used model impurities rather than full manufacturing streams or clinical products.

Simplified

Messenger ribonucleic acid (mRNA) therapeutics produced by in vitro transcription must be purified to remove residual enzymes and free nucleotides. This study examines the use of high-performance countercurrent membrane purification (HPCMP) for the purification of mRNA therapeutics based on differences in the rate of diffusion across semipermeable polyethersulfone hollow fiber membranes. Experiments were performed using two model mRNA constructs using cytosine triphosphates (CTPs) and Proteinase K as model impurities. HPCMP achieved 99.7% removal of CTPs using a residence time of 60 min with no measurable loss of mRNA. Proteinase K removal by HPCMP was reduced in the presence of mRNA due to complexation between the positively charged protein and the negatively charged mRNA, an effect that was independently confirmed by dynamic light scattering and stirred cell diafiltration experiments. The HPCMP process could be operated continuously for more than 24 h without membrane fouling with stable mRNA yield (> 97%) and Proteinase K removal (> 94%). These results clearly demonstrate the feasibility of using HPCMP for continuous purification of mRNA therapeutics.